Company News for July 28, 2009 – Corporate Summary
Zacks Market Commentaries (July 28th, 2009) Writes:
• Amgen (NASDAQ:AMGN) reported better-than-estimated earnings of $1.29 a share, 13 cents above estimates, after yesterday's market close, as the company benefited from its arthritis drug and tax benefits. The firm raised its full-year earnings outlook to $4.80-$4.95 per share from $4.55-$4.75 per share and consensus estimates of $4.57
• This morning’s report indicate Amgen (NASDAQ:AMGN) and GlaxoSmithKline (NYSE:GSK) have agreed to jointly market an osteoporosis treatment, that could generate $2 billion in annual sales within ten years if given regulatory approval
• Barclays (NYSE:BCS) cut Boeing (NYSE:BA) shares to "equal weight" from "overweight", on delays and undetermined cost overruns in its Dreamliner program. Price targets were cut from $60 to $46
• Goldman Sachs (NYSE:GS) raised its rating on the US steel sector to "buy" from "neutral," noting a faster-than-expected recovery in world markets and a leaner US supply chain. Analysts upgraded US Steel (NYSE:X) in advance of today's earnings release to
...Air Products and Chemicals, Amgen, Analysts, Arthritis, Barclays, Boeing, cent;, Dreamliner, Glaxosmithkline, Goldman Sachs, Ibm, JP-Morgan, Market Commentary, Osteoporosis, Osteoporosis Treatment, SPSS, Stocks to Watch, Supply Chain, U.S. Steel, Under Armour, United States, USD, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)



